Avalo Therapeutics Inc
Statements
Cash Flow
Avalo Therapeutics Inc (AVTX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -18 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 16 | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.7 | -3.4 | -3.7 | -2.2 | -1.8 | 19 | -0.3 | -0.3 | -0.5 | -2.0 | -3.1 | -6.7 | -7.6 | -1.7 | -5.7 | -8.6 | -12 | -14 | -18 | -19 | -16 | -17 | -16 | -12 | 5.7 | -3.9 | -10 | -11 | -6.8 | -2.8 | -6.2 | -16 | -12 | -15 | -9.5 | -11 | -16 | -14 | -18 | -18 | -66 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 | 1.2 | 1.1 | 1.2 | 1.1 | 1.1 | 1.1 | 0.6 | 0.5 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.3 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | |
| 0.2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.2 | 0.6 | 0.9 | 0.6 | 0.6 | 0.5 | 0.8 | 0.6 | 1.1 | 2.8 | 1.4 | 1.4 | 1.4 | 3.1 | 1.8 | 1.9 | 5.3 | 0.7 | 0.7 | 0.8 | 0.9 | 0.9 | 1.0 | 0.8 | 0.6 | 0.5 | 1.8 | 2.9 | 3.2 | 2.7 | 3.2 | 4.5 | 3.6 | 5.3 | 17 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.9 | 1.6 | 1.5 | 3.2 | 1.8 | 1.9 | 5.3 | 1.7 | 0.7 | 0.9 | 1.0 | 0.9 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -0.4 | 2.3 | -2.2 | -0.6 | -0.2 | 0.1 | 1.9 | 1.7 | 3.1 | 2.0 | 2.4 | -2.6 | -5.3 | 3.5 | -2.9 | 0.1 | -0.7 | -0.9 | 10 | -5.7 | -1.5 | -0.4 | 0.2 | -1.5 | 1.4 | 4.6 | -1.5 | -4.2 | -3.6 | 0.1 | -1.3 | -1.3 | -1.5 | -0.6 | 1.2 | 3.6 | -1.1 | 0.2 | -1.1 | 3.0 | 0.9 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.5 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | 0.0 | 0.1 | 0.2 | 0.2 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| 0.0 | 0.0 | 0.0 | 0.0 | – | 0.0 | 0.0 | 0.0 | 1.4 | -0.5 | -0.2 | -0.1 | 0.0 | -0.2 | -1.3 | 13 | -0.1 | -0.4 | 0.0 | -0.1 | -0.1 | 0.0 | -0.1 | -0.1 | 0.0 | -0.1 | -0.1 | 0.2 | – | -0.2 | 0.4 | 0.4 | – | – | – | -71 | -13 | 2.4 | 26 | -330 | -315 | |
| – | – | – | – | – | – | – | – | – | – | – | – | 0.0 | 0.6 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | 0.0 | – | – | – | – | – | – | 0.0 | 0.0 | – | – | 0.0 | 0.2 | 38 | 0.2 | 0.0 | 0.4 | – | – | – | 0.1 | 14 | – | – | 0.1 | – | – | – | – | – | 0.0 | – | 0.0 | – | 0.1 | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 20 | 20 | 20 | 20 | 13 | -15 | -15 | -15 | -6.0 | -6.0 | -6.0 | -6.0 | – | – | – | – | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | |
| -1.0 | 0.4 | 0.0 | 0.1 | 4.2 | -0.6 | 0.4 | 0.0 | 3.8 | 6.2 | 8.8 | 0.1 | 3.5 | 0.1 | 9.1 | 35 | 0.0 | 0.2 | 38 | 21 | 48 | 0.1 | -15 | -15 | 0.1 | 0.1 | 14 | 0.6 | 11 | 0.0 | 109 | -0.5 | 0.0 | 68 | 0.0 | -0.5 | 14 | 0.7 | 1.4 | 839 | 856 | |
| -4.7 | -3.1 | -3.7 | -2.1 | 2.5 | 18 | 0.1 | -0.3 | 4.7 | 3.7 | 5.5 | -6.7 | -4.1 | -1.7 | 2.1 | 40 | -12 | -15 | 19 | 2.0 | 31 | -17 | -16 | -27 | 5.7 | -3.9 | 3.6 | -10 | 3.9 | -2.8 | 103 | -17 | -12 | 53 | -9.5 | -83 | -15 | -11 | 9.2 | 491 | 474 | |
| -3.7 | -3.4 | -3.7 | -2.2 | -1.8 | 19 | -0.3 | -0.3 | -0.6 | -2.5 | -3.3 | -6.8 | -7.6 | -1.7 | -5.7 | -8.6 | -12 | -14 | -18 | -19 | -16 | -17 | -16 | -13 | 5.7 | -4.0 | -10 | -11 | -6.8 | -2.9 | -6.2 | -16 | -12 | -15 | -9.5 | -11 | -16 | -14 | -18 | -18 | -66 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.